, Volume 18, Issue 6, pp 581–589 | Cite as

Association between Abciximab and Length of Stay in Intensive Care for Patients Undergoing Percutaneous Coronary Intervention

A 2-Stage Econometric Model in a Naturalistic Setting
  • Maureen J. Lage
  • Beth L. Barber
  • Mohan Bala
  • Patrick L. McCollam
  • Daniel E. Ball
Original Research Article


Objective: To examine the effect of abciximab treatment on intensive care length of stay for patients undergoing percutaneous coronary intervention (PCI).

Design and setting: A retrospective study conducted in a naturalistic setting.

Methods: A 2-stage econometric model was used to control for the influence of possible selection bias across categories of patients and for both observable and unobservable factors correlated with each patient’s treatment selection and length of stay in intensive care. Multivariate analysis was applied to control for a wide range of factors (patient demographics, insurance provider, health conditions, admission and discharge information, and hospital characteristics) that may influence intensive care length of stay. Retrospective data were obtained from HCIA’s Clinical Pathways Database.

Participants: Patients (n = 13 364) who were hospitalised in any of 87 hospitals across the US over the period from October 1, 1995 to December 1, 1996.

Results: After controlling for high-risk indications and selection bias, results indicated that administration of abciximab was associated with a significantly shorter length of stay in intensive care compared with not administering a GPIIb/IIIa inhibitor (0.45 fewer days; p ≤ 0.0001). In a subgroup analysis of patients having an acute myocardial infarction (n = 4793), administration of abciximab was also associated with a significantly shorter intensive care stay (0.27 fewer days; p < 0.0001).

Conclusion: Results of this study indicate that the administration of abciximab is associated with a reduction in the length of stay in intensive care. This reduction implies potential cost offsets for patients undergoing PCI who receive abciximab.


Percutaneous Coronary Intervention Abciximab Hospital Characteristic Standard Metropolitan Statistical Area Intensive Care Stay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Funding provided by Eli Lilly and Company.


  1. 1.
    Mak KH, Challapalli R, Eisenberg MJ, et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary sapheneous vein grafts. Am J Cardiol 1997; 80: 985–8PubMedCrossRefGoogle Scholar
  2. 2.
    Lefkovitz J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 70: 1045–51CrossRefGoogle Scholar
  3. 3.
    Califf RM, Lincoff AM, Tcheng JE, et al. An overview of the results of the EPIC trial. Eur Heart J 1995; 16 Suppl. L: 43–9Google Scholar
  4. 4.
    Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479–84PubMedCrossRefGoogle Scholar
  5. 5.
    Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 1998; 19 Suppl. D: D10-D21Google Scholar
  6. 6.
    EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336 (24): 1689–96CrossRefGoogle Scholar
  7. 7.
    Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 31: 35–40CrossRefGoogle Scholar
  8. 8.
    Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet 1999; 354: 2019–24PubMedCrossRefGoogle Scholar
  9. 9.
    CAPTURE Study. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429–35CrossRefGoogle Scholar
  10. 10.
    Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation 1998; 97: 857–64PubMedCrossRefGoogle Scholar
  11. 11.
    Edbrooke D, Hibbert C, Ridley S, et al. The development of a method for comparative costing of individual intensive care units. Anesthesia 1999; 54: 110–20CrossRefGoogle Scholar
  12. 12.
    Halpern NA, Bettes L, Greenstein R. Federal and nationwide intensive care units and healthcare costs: 1986–1992. Crit Care Med 1994; 22: 2001–7PubMedGoogle Scholar
  13. 13.
    Weissman C. Analyzing intensive care unit length of stay data: problems and possible solutions. Crit Care Med 1997; 25: 1594–600PubMedCrossRefGoogle Scholar
  14. 14.
    Knaus WA, Wagner DP, Zimmerman JE, et al. Variations in mortality and length of stay in intensive care units. Ann Intern Med 1993; 118 (10): 755–61Google Scholar
  15. 15.
    Zimmerman JE, Shortell JM, Rousseau DM, et al. Improving intensive care: observations based on organizational case studies in nine intensive care units: a prospective, multicenter study. Crit Care Med 1993; 21 (10): 1443–51PubMedCrossRefGoogle Scholar
  16. 16.
    Lee LF. Generalized models with selectivity. Econometrica 1983; 51: 507–12CrossRefGoogle Scholar
  17. 17.
    Matsui K, Goldman L, Johnson PA, et al. Comorbidity as a correlate of length of stay for hospitalized patients with acute chest pain. J Gen Intern Med 1996; 11: 262–8PubMedCrossRefGoogle Scholar
  18. 18.
    Every NR, Spertus J, Fihn SD, et al. Length of hospital stay after acute myocardial infarction in the myocardial infarction triage and intervention (MITI) project registry. J Am Coll Cardiol 1996; 28: 287–93PubMedCrossRefGoogle Scholar
  19. 19.
    Greene WH. Econometric analysis. Upper Saddle River (NJ): Prentice-Hall, 1997Google Scholar
  20. 20.
    Heckman J. Sample selection bias as a specification error. Econometrica 1979; 47: 153–61CrossRefGoogle Scholar
  21. 21.
    Barnow BS, Cain GG, Goldberger AS. Issues in the analysis of selectivity bias. In: Stromsdorfer EW, Farkas G, editors. Evaluation studies review annual. Vol. 5. Beverly Hills (CA): Sage Publications, 1980Google Scholar
  22. 22.
    Greene WH. LIMDEP. Version 7.0 user’s manual. Plainview (NY): Econometric Software, 1998Google Scholar
  23. 23.
    Melfi C, Holleman E, Arthur D, et al. Selecting a patient characteristic index for the prediction of medical outcomes using administrative claims data. J Clin Epidemiol 1995; 48: 917–26PubMedCrossRefGoogle Scholar
  24. 24.
    Weitzman S, Cooper L, Chambless L, et al. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states. Am J Cardiol 1997: 79: 722–6PubMedCrossRefGoogle Scholar
  25. 25.
    Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991: 325: 221–5PubMedCrossRefGoogle Scholar
  26. 26.
    Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. N Engl J Med 1991: 325: 226–30PubMedCrossRefGoogle Scholar
  27. 27.
    Maynard C, Every NR, Martin RS, et al. Long-term implications of racial differences in the use of revascularization procedures (the Myocardial Infarction Triage and Intervention Registry). Am Heart J 1997: 133 (6): 656–62PubMedCrossRefGoogle Scholar
  28. 28.
    Peterson ED, Wright SM, Daley J, et al. Racial variation in cardiac procedure use and survival following myocardial infarction in the Department of Veterans Affairs. JAMA 1994: 271: 1175–80PubMedCrossRefGoogle Scholar
  29. 29.
    Ayanian JZ, Udvarheyli IS, Gastonis CA, et al. Racial differences in the use of revascularization procedures after coronary angioplasty. JAMA 1993: 269: 2642–6PubMedCrossRefGoogle Scholar
  30. 30.
    Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease inMassachusetts. JAMA 1989: 261: 253–7PubMedCrossRefGoogle Scholar
  31. 31.
    Braunwald E, Maseri P, Armstrong PW, et al. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J 1998; 19 Suppl. D: D22-D30Google Scholar
  32. 32.
    Lage MJ, Barber BL, Bowman L, et al. Shorter hospital stays for angioplasty patients who receive abciximab. J Invasive Cardiol 2000; 12: 179–86PubMedGoogle Scholar
  33. 33.
    van Hout BA, Bowman L, Zelinger DJ, et al. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Eur Heart J 1998; 19 Suppl. D: D59-D66Google Scholar
  34. 34.
    Goklaney AK, Murphy JD, Hillegass WB. Abciximab therapy in percutaneous intervention: economic issues in the United States. Eur Heart J 1998; 19 Suppl. D: D52-D58Google Scholar
  35. 35.
    Becker RB, Zimmerman JE, Knaus WE, et al. The use of APACHE III to evaluate ICU length of stay, resource use, and mortality after coronary artery by-pass surgery. J Cardiovasc Surg 1995; 36: 1–11Google Scholar
  36. 36.
    McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality?: analysis using instrumental variables. JAMA1994; 272: 859–66PubMedCrossRefGoogle Scholar
  37. 37.
    Takala J, Roukonen E. Cost and resource utilization in intensive care. In: Vincent JL, editor. Yearbook of intensive care and emergency medicine. Berlin, Heidelberg, New York (NY): Springer, 1997: 885–95Google Scholar
  38. 38.
    van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients: an indirect analysis for the Netherlands. Eur Heart J 1995; 16 Suppl. L: 81–5PubMedCrossRefGoogle Scholar
  39. 39.
    Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30: 149–56PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Maureen J. Lage
    • 1
  • Beth L. Barber
    • 2
  • Mohan Bala
    • 3
  • Patrick L. McCollam
    • 2
  • Daniel E. Ball
    • 2
  1. 1.Department of EconomicsMiami UniversityOxfordUSA
  2. 2.Health Outcomes Evaluation GroupEli Lilly and Company, Lilly Corporate CenterIndianapolisUSA
  3. 3.Clinical ResearchCentocor Inc.MalvernUSA

Personalised recommendations